Oppenheimer Assumes Nurix Therapeutics at Outperform, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Mark Breidenbach assumes Nurix Therapeutics (NASDAQ:NRIX) with an Outperform rating and announces a price target of $25.
June 26, 2023 | 9:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer assumes Nurix Therapeutics with an Outperform rating and sets a price target of $25.
The news of Oppenheimer assuming Nurix Therapeutics with an Outperform rating and setting a price target of $25 is likely to have a positive impact on the stock price in the short term. This is because the Outperform rating indicates that the analyst believes the stock will outperform its peers, and the price target of $25 suggests potential upside from the current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100